• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Nuvig Therapeutics Appoints Julie Smith Chief Executive Officer

    1/4/23 9:00:00 AM ET
    $EXEL
    $STOK
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $EXEL alert in real time by email

    Nuvig Therapeutics, Inc., a biopharma company developing proprietary recombinant human therapeutics for patients with autoimmune diseases, today announced the appointment of Julie Anne Smith as Chief Executive Officer (CEO) and member of the Board of Directors. Ms. Smith has over 20 years of experience in the life science industry, with a focus on leading private and public biotech companies through development and commercialization of therapeutics for orphan diseases. Pamela Conley, Ph.D., cofounder and founding CEO of Nuvig Therapeutics, will serve as the Company's Chief Scientific Officer.

    "The board is very grateful to Pam for leading Nuvig from inception to this exciting inflection point, as the company enters IND-enabling activities for its lead program," said Kenneth Harrison, Ph.D., Director of Nuvig Therapeutics and Partner at Novo Ventures. "We are excited by the dynamic leadership, vision, and experience Julie brings to the company and look forward to working closely with her to advance Nuvig's therapies to patients."

    Nuvig's lead program is a novel recombinant human antibody fragment engineered to induce immune modulatory mechanisms that restore immune homeostasis and control inflammation in autoimmune diseases. Nuvig is extending this technology to build a pipeline of differentiated protein therapeutics that can be used in the context of varied but well-defined inflammatory and autoimmune diseases.

    "I'm delighted to join Nuvig at this pivotal time as the team has received strong investor support and rapidly advanced its novel technology to the IND-enabling stage," said Ms. Smith. "I look forward to working with Pam and the team to propel our development candidates into the clinic with the goal of providing new therapeutic options for autoimmune diseases without broad immunosuppression."

    Prior to Nuvig, Ms. Smith served as President and CEO of ESCAPE Bio, a biotech company developing precisely targeted therapies for genetic forms of neurodegeneration. She previously served as President and CEO of Raptor Pharmaceuticals, which developed and commercialized therapies for the orphan disease nephropathic cystinosis and chronic pulmonary infections before its acquisition by Horizon Pharmaceuticals. Ms. Smith also served as Chief Commercial Officer of Enobia Pharmaceuticals until it was acquired by Alexion Pharmaceuticals. Earlier in her career, she held roles at Jazz Pharmaceuticals, Genzyme, Novazyme, and Bristol-Myers Squibb. Ms. Smith serves as a director on the Boards of Exelixis (NASDAQ:EXEL) and Stoke Therapeutics (NASDAQ:STOK). Ms. Smith obtained her B.S. in biology from Cornell University.

    About Nuvig Therapeutics

    Nuvig Therapeutics is advancing innovative and transformational therapies that are designed to induce natural mechanisms to restore immune homeostasis, rebalance immune function following inflammation, and improve the treatment options for patients. Nuvig is building a pipeline of novel immune therapeutics for chronic inflammatory and autoimmune diseases. For more info, visit www.nuvigtherapeutics.com.

    View source version on businesswire.com: https://www.businesswire.com/news/home/20230104005134/en/

    Get the next $EXEL alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $EXEL
    $STOK

    CompanyDatePrice TargetRatingAnalyst
    Exelixis Inc.
    $EXEL
    10/21/2025$48.00Market Perform → Outperform
    Leerink Partners
    Exelixis Inc.
    $EXEL
    9/19/2025$40.00Equal Weight
    Barclays
    Exelixis Inc.
    $EXEL
    9/17/2025$40.00Equal Weight
    Barclays
    Exelixis Inc.
    $EXEL
    9/17/2025$47.00Buy
    Goldman
    Stoke Therapeutics Inc.
    $STOK
    7/18/2025$30.00Buy
    Jefferies
    Exelixis Inc.
    $EXEL
    7/8/2025$45.00 → $50.00Outperform → Sector Perform
    RBC Capital Mkts
    Exelixis Inc.
    $EXEL
    6/24/2025$60.00Equal-Weight → Overweight
    Stephens
    Exelixis Inc.
    $EXEL
    2/24/2025$36.00Overweight → Equal Weight
    Wells Fargo
    More analyst ratings

    $EXEL
    $STOK
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    FDA Approval for CABOMETYX issued to EXELIXIS INC

    Submission status for EXELIXIS INC's drug CABOMETYX (SUPPL-16) with active ingredient CABOZANTINIB S-MALATE has changed to 'Approval' on 09/20/2023. Application Category: NDA, Application Number: 208692, Application Classification: Labeling

    9/21/23 4:37:02 AM ET
    $EXEL
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    FDA Approval for CABOMETYX issued to EXELIXIS INC

    Submission status for EXELIXIS INC's drug CABOMETYX (SUPPL-14) with active ingredient CABOZANTINIB S-MALATE has changed to 'Approval' on 07/14/2022. Application Category: NDA, Application Number: 208692, Application Classification: Efficacy

    7/15/22 4:38:40 AM ET
    $EXEL
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    FDA Approval for CABOMETYX issued to EXELIXIS INC

    Submission status for EXELIXIS INC's drug CABOMETYX (SUPPL-12) with active ingredient CABOZANTINIB S-MALATE has changed to 'Approval' on 09/17/2021. Application Category: NDA, Application Number: 208692, Application Classification: Efficacy

    9/20/21 3:53:29 PM ET
    $EXEL
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $EXEL
    $STOK
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Chief Executive Officer Smith Ian F

    4 - Stoke Therapeutics, Inc. (0001623526) (Issuer)

    10/14/25 4:16:10 PM ET
    $STOK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    EVP, Research & Development Aftab Dana was granted 50,673 shares, increasing direct ownership by 8% to 713,161 units (SEC Form 4)

    4 - EXELIXIS, INC. (0000939767) (Issuer)

    10/10/25 6:57:17 PM ET
    $EXEL
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Director Kaye Edward M. Md sold $750,000 worth of shares (25,000 units at $30.00) and exercised 25,000 shares at a strike of $0.60 (SEC Form 4)

    4 - Stoke Therapeutics, Inc. (0001623526) (Issuer)

    10/10/25 4:12:24 PM ET
    $STOK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $EXEL
    $STOK
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Exelixis upgraded by Leerink Partners with a new price target

    Leerink Partners upgraded Exelixis from Market Perform to Outperform and set a new price target of $48.00

    10/21/25 7:13:23 AM ET
    $EXEL
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Barclays resumed coverage on Exelixis with a new price target

    Barclays resumed coverage of Exelixis with a rating of Equal Weight and set a new price target of $40.00

    9/19/25 7:43:42 AM ET
    $EXEL
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Barclays resumed coverage on Exelixis with a new price target

    Barclays resumed coverage of Exelixis with a rating of Equal Weight and set a new price target of $40.00

    9/17/25 8:02:00 AM ET
    $EXEL
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $EXEL
    $STOK
    SEC Filings

    View All

    SEC Form 144 filed by Stoke Therapeutics Inc.

    144 - Stoke Therapeutics, Inc. (0001623526) (Subject)

    10/8/25 4:20:36 PM ET
    $STOK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 8-K filed by Stoke Therapeutics Inc.

    8-K - Stoke Therapeutics, Inc. (0001623526) (Filer)

    10/6/25 7:30:15 AM ET
    $STOK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 144 filed by Stoke Therapeutics Inc.

    144 - Stoke Therapeutics, Inc. (0001623526) (Subject)

    10/3/25 4:35:12 PM ET
    $STOK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $EXEL
    $STOK
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Exelixis to Release Third Quarter 2025 Financial Results on Tuesday, November 4, 2025

    – Conference Call and Webcast to Follow at 5:00 p.m. ET / 2:00 p.m. PT – Exelixis, Inc. (NASDAQ:EXEL) announced today that its third quarter 2025 financial results will be released on Tuesday, November 4, 2025 after the markets close. At 5:00 p.m. ET / 2:00 p.m. PT, Exelixis management will host a conference call and webcast to discuss the results and provide a general business update. Access to the event is available via the Internet from the company's website. To access the conference call, please register using this link. Upon registration, a dial-in number and unique PIN will be provided to join the call. To access the live webcast link, log onto www.exelixis.com and proceed to the

    10/21/25 4:05:00 PM ET
    $EXEL
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    The Institute for Follicular Lymphoma Innovation (IFLI) Appoints Innovative Leaders Mehrdad Mobasher, M.D., M.P.H., and Carol O'Hear, M.D., Ph.D., as Executive Partners

    DIAMOND BAR, Calif., Oct. 21, 2025 /PRNewswire/ -- The Institute for Follicular Lymphoma Innovation (IFLI), a global, non-profit, private foundation dedicated to accelerating the development of innovative treatment options for patients with follicular lymphoma (FL)., today announced the appointments of Mehrdad Mobasher, M.D., M.P.H., and Carol O'Hear, M.D., Ph.D., as Executive Partners. "I believe Carol and Mehrdad will be exceptional partners to the IFLI team and portfolio as they bring decades of strategic leadership and drug development expertise," said David McCullagh, Man

    10/21/25 8:05:00 AM ET
    $CRVS
    $DNA
    $EXEL
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Biological Products (No Diagnostic Substances)

    SynOx Therapeutics Strengthens Board of Directors with Leading Experts in Commercialisation and Corporate Development Amid Continued Corporate Progress

    DUBLIN and OXFORD, United Kingdom and PHILADELPHIA, Oct. 21, 2025 (GLOBE NEWSWIRE) -- SynOx Therapeutics Limited ("SynOx"), a late-stage clinical biopharmaceutical company developing emactuzumab for Tenosynovial Giant Cell Tumours (TGCT), today announced the appointments of Charles "Chip" R. Romp and Tom J. Heyman to its Board of Directors. These appointments further align SynOx's business with its forward strategy as the company nears topline data for emactuzumab and continues its focus on regulatory and commercial activities. In August 2025, SynOx completed enrollment in the Phase 3 TANGENT clinical trial; topline data are expected in the first quarter of 2026. Ray Barlow, Chief Execu

    10/21/25 7:00:00 AM ET
    $AKRO
    $EXEL
    $LEGN
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Biological Products (No Diagnostic Substances)

    $EXEL
    $STOK
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Johnson David Edward bought $8,733,955 worth of shares (425,000 units at $20.55) (SEC Form 4)

    4 - EXELIXIS, INC. (0000939767) (Issuer)

    5/30/24 7:50:14 PM ET
    $EXEL
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Johnson David Edward bought $3,932,734 worth of shares (190,000 units at $20.70) (SEC Form 4)

    4 - EXELIXIS, INC. (0000939767) (Issuer)

    2/22/24 5:08:50 PM ET
    $EXEL
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Johnson David Edward sold $2,602,038 worth of shares (120,409 units at $21.61) and bought $2,602,038 worth of shares (120,409 units at $21.61) (SEC Form 4)

    4 - EXELIXIS, INC. (0000939767) (Issuer)

    11/29/23 4:30:29 PM ET
    $EXEL
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $EXEL
    $STOK
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Stoke Therapeutics Inc.

    SC 13G/A - Stoke Therapeutics, Inc. (0001623526) (Subject)

    11/14/24 9:00:58 PM ET
    $STOK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by Stoke Therapeutics Inc.

    SC 13G - Stoke Therapeutics, Inc. (0001623526) (Subject)

    11/14/24 4:24:49 PM ET
    $STOK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Stoke Therapeutics Inc.

    SC 13G/A - Stoke Therapeutics, Inc. (0001623526) (Subject)

    11/14/24 9:00:12 AM ET
    $STOK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $EXEL
    $STOK
    Leadership Updates

    Live Leadership Updates

    View All

    The Institute for Follicular Lymphoma Innovation (IFLI) Appoints Innovative Leaders Mehrdad Mobasher, M.D., M.P.H., and Carol O'Hear, M.D., Ph.D., as Executive Partners

    DIAMOND BAR, Calif., Oct. 21, 2025 /PRNewswire/ -- The Institute for Follicular Lymphoma Innovation (IFLI), a global, non-profit, private foundation dedicated to accelerating the development of innovative treatment options for patients with follicular lymphoma (FL)., today announced the appointments of Mehrdad Mobasher, M.D., M.P.H., and Carol O'Hear, M.D., Ph.D., as Executive Partners. "I believe Carol and Mehrdad will be exceptional partners to the IFLI team and portfolio as they bring decades of strategic leadership and drug development expertise," said David McCullagh, Man

    10/21/25 8:05:00 AM ET
    $CRVS
    $DNA
    $EXEL
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Biological Products (No Diagnostic Substances)

    Exelixis Announces Appointment of Dana T. Aftab, Ph.D. as Executive Vice President, Research and Development

    – Dr. Aftab has served for over 25 years at Exelixis and has been instrumental in driving the company's scientific innovation and development activities – Exelixis, Inc. (NASDAQ:EXEL) today announced it has appointed Dana T. Aftab, Ph.D., as its Executive Vice President, Research and Development. In this new role, Dr. Aftab will oversee all aspects of the company's drug discovery, translational research, product development and medical affairs activities. "Dana has been an integral part of the Exelixis team for more than 25 years, with deep expertise that spans the drug discovery and development continuum. He's been a key contributor to many of Exelixis' most important milestones, inclu

    8/29/25 5:47:00 PM ET
    $EXEL
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amid NCI Budget Fears, Emerging Oncology Stocks Gain Attention

    Equity Insider News CommentaryIssued on behalf of Oncolytics Biotech Inc. VANCOUVER, BC, July 8, 2025 /PRNewswire/ -- Equity Insider News Commentary – As cancer rates climb and drug costs continue to soar, pressure is mounting on the private sector to drive innovation. Now, cancer experts are alarmed over a "gut wrenching" plan from the U.S. government to cut nearly 40% of National Cancer Institute funding, even as the price of oncology treatments pushes new limits—raising urgent concerns about access and affordability. In this shifting landscape, investors are turning their attention to a new wave of biotechs and specialty care providers developing breakthrough therapies and smarter care mo

    7/8/25 10:25:00 AM ET
    $CELC
    $CTOR
    $EXEL
    Medical Specialities
    Health Care
    Biotechnology: Pharmaceutical Preparations
    Biotechnology: Biological Products (No Diagnostic Substances)

    $EXEL
    $STOK
    Financials

    Live finance-specific insights

    View All

    Exelixis to Release Third Quarter 2025 Financial Results on Tuesday, November 4, 2025

    – Conference Call and Webcast to Follow at 5:00 p.m. ET / 2:00 p.m. PT – Exelixis, Inc. (NASDAQ:EXEL) announced today that its third quarter 2025 financial results will be released on Tuesday, November 4, 2025 after the markets close. At 5:00 p.m. ET / 2:00 p.m. PT, Exelixis management will host a conference call and webcast to discuss the results and provide a general business update. Access to the event is available via the Internet from the company's website. To access the conference call, please register using this link. Upon registration, a dial-in number and unique PIN will be provided to join the call. To access the live webcast link, log onto www.exelixis.com and proceed to the

    10/21/25 4:05:00 PM ET
    $EXEL
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Stoke Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Updates

    – First patient dosed in the Phase 3 EMPEROR study of zorevunersen in patients with Dravet syndrome – – New 3-year zorevunersen OLE data provide additional support for disease modification: continuing and durable reductions in seizures and improvements in cognition and behavior and generally well tolerated – – Phase 1 study of STK-002 initiated in patients with Autosomal Dominant Optic Atrophy (ADOA), the most common inherited optic nerve disorder – – As of June 30, 2025, the Company had $355.0 million in cash, cash equivalents, and marketable securities, anticipated to fund operations to mid-2028 and into launch readiness – – Webcast and conference call for analysts and investors a

    8/12/25 4:01:00 PM ET
    $STOK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Stoke Therapeutics to Host Webcast and Conference Call to Discuss Second Quarter 2025 Business and Financial Updates

    Stoke Therapeutics, Inc. (NASDAQ:STOK) is a biotechnology company dedicated to restoring protein expression by harnessing the body's potential with RNA medicine and has a lead investigational medicine, zorevunersen, in development as a first-in-class potential disease-modifying treatment for Dravet syndrome. The Company today announced that management will host a webcast and conference call for analysts and investors on Tuesday, August 12, 2025, at 4:30 p.m. ET, to discuss second quarter 2025 business and financial updates. The webcast will be available on the Investors & News section of Stoke's website at https://investor.stoketherapeutics.com/. Research analysts who plan to join the cal

    8/7/25 7:00:00 AM ET
    $STOK
    Biotechnology: Pharmaceutical Preparations
    Health Care